Leverage remains elevated with debt-to-equity at 2.55 and total debt of $119.3B, while retained earnings plummeted 90% to $1.1B in 2026Q1, signaling deteriorating equity quality and a thinner liquidity buffer as cash fell to $17.0B.
| Total Current Assets | 17.76B | 101.4B | 655.62B | 386.36B | 79.39B | 83.91B | 60.54B | 41.92B | 36.9B | 36.11B | 33.92B | 49.81B | 37.54B |
| Cash & Short-Term Investments | 3.47B | 25.98B | 214.97B | 108.74B | 13.18B | 23.24B | 19.68B | 10.03B | 8.94B | 11.74B | 9.36B | 18.84B | 14.91B |
| Cash Only | 3.47B | 25.11B | 214.97B | 108.74B | 13.18B | 23.24B | 19.68B | 10.03B | 8.94B | 11.74B | 9.36B | 18.84B | 8.37B |
| Short-Term Investments | 0 | 877.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.54B |
| Accounts Receivable | 3.56B | 29.4B | 143.05B | 80.69B | 20.23B | 19.88B | 14B | 11.14B | 9.66B | 9.33B | 9.59B | 12.12B | 9.58B |
| Days Sales Outstanding | 19.8 | 22.78 | 125.22 | 80.95 | 19.24 | 20.01 | 18.91 | 19.87 | 19.4 | 20.88 | 20.54 | 27.15 | 29.02 |
| Inventory | 7B | 43.63B | 253.66B | 162.13B | 37.85B | 33.95B | 22.7B | 17.35B | 14.5B | 12.45B | 12.28B | 13.98B | 9.84B |
| Days Inventory Outstanding | 37.9 | 38.77 | 261.41 | 182.55 | 42.78 | 42.15 | 36.83 | 36.69 | 34.08 | 32.6 | 30.07 | 36.37 | 35.29 |
| Other Current Assets | 3.74B | 2.38B | 43.94B | 34.8B | 8.12B | 6.85B | 4.15B | 3.41B | 3.8B | 2.58B | 2.69B | 4.86B | 3.03B |
| Total Non-Current Assets | 28.08B | 146.94B | 902.35B | 626.82B | 128.72B | 123.34B | 103.26B | 84.42B | 77.25B | 72.59B | 68.9B | 72.69B | 44.5B |
| Property, Plant & Equipment | 16.04B | 62.58B | 532.12B | 360.63B | 73.16B | 67.05B | 54.74B | 44.06B | 36.28B | 34.53B | 34.09B | 36.48B | 24.73B |
| Fixed Asset Turnover | 7.00x | 7.53x | 0.78x | 1.01x | 5.25x | 5.41x | 4.94x | 4.64x | 5.01x | 4.73x | 5.00x | 4.47x | 4.87x |
| Goodwill | 5.98B | 32.19B | 207.44B | 145.27B | 30.41B | 32.56B | 28.89B | 24.5B | 23.78B | 22.49B | 21.92B | 24.41B | 12.99B |
| Intangible Assets | 1.78B | 10.04B | 69.05B | 47.25B | 10.33B | 12B | 7.82B | 6.05B | 5.82B | 5.51B | 5.01B | 6.89B | 2.45B |
| Long-Term Investments | 53.77B | 26.13B | 1.47B | 1.35B | 294.84M | 243.19M | 171.1M | 93.63M | 84.97M | 64.01M | 362.63M | 354.13M | 295.35M |
| Other Non-Current Assets | 3.34B | 13B | 92.28B | 72.31B | 14.52B | 11.48B | 11.65B | 9.71B | 11.29B | 10B | 7.52B | 4.55B | 4.04B |
| Total Assets | 45.84B | 248.34B | 1.56T | 1.01T | 208.11B | 207.25B | 163.8B | 126.34B | 114.15B | 108.7B | 102.82B | 122.5B | 82.04B |
| Asset Turnover | 2.00x | 1.90x | 0.27x | 0.36x | 1.85x | 1.75x | 1.65x | 1.62x | 1.59x | 1.50x | 1.66x | 1.33x | 1.47x |
| Asset Growth % | -80.03% | -84.06% | 53.77% | 386.84% | 0.41% | 26.53% | 29.65% | 10.68% | 5.01% | 5.72% | -16.07% | 49.31% | - |
| Total Current Liabilities | 11.58B | 63.48B | 446.39B | 235.51B | 55.16B | 59.81B | 40.84B | 28.46B | 21.6B | 29.18B | 33.35B | 40.14B | 24.87B |
| Accounts Payable | 5.85B | 40.33B | 209.29B | 125.1B | 31.01B | 30.22B | 22.2B | 15.44B | 12.17B | 9.99B | 10.72B | 12.42B | 6.94B |
| Days Payables Outstanding | 31.26 | 35.83 | 215.69 | 140.85 | 35.05 | 37.51 | 36.01 | 32.65 | 28.58 | 26.17 | 26.24 | 32.31 | 24.89 |
| Short-Term Debt | 13.08B | 6.53B | 107.72B | 43.78B | 11.3B | 14.6B | 6.66B | 4.09B | 3.83B | 13.53B | 18.15B | 20.91B | 13.69B |
| Deferred Revenue (Current) | 378.94M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | -9.95B | 6.45B | 57.19B | 23.95B | 4.09B | 5.66B | 4.33B | 3.37B | 1.57B | 2.17B | 1.46B | 3.55B | 2.13B |
| Current Ratio | 1.53x | 1.60x | 1.47x | 1.64x | 1.44x | 1.40x | 1.48x | 1.47x | 1.71x | 1.24x | 1.02x | 1.24x | 1.51x |
| Quick Ratio | 0.93x | 0.91x | 0.90x | 0.95x | 0.75x | 0.84x | 0.93x | 0.86x | 1.04x | 0.81x | 0.65x | 0.89x | 1.11x |
| Cash Conversion Cycle | 26.44 | 25.72 | 170.95 | 122.65 | 26.97 | 24.65 | 19.73 | 23.91 | 24.89 | 27.32 | 24.37 | 31.22 | 39.41 |
| Total Non-Current Liabilities | 130.26B | 132.5B | 800.1B | 546.66B | 103.14B | 99.65B | 79.42B | 65.4B | 64.6B | 53.38B | 45.95B | 52.74B | 31.53B |
| Long-Term Debt | 110.19B | 111.41B | 660.27B | 454.68B | 84.13B | 80.6B | 61.34B | 50.95B | 53.23B | 43.5B | 38.11B | 44.98B | 26.39B |
| Capital Lease Obligations | 30.13B | 7.77B | 53.55B | 35.42B | 7.2B | 6.78B | 4.81B | 3.77B | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 18.34B | 6.43B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 12.69B | 6.89B | 86.28B | 56.56B | 11.82B | 12.26B | 13.27B | 10.68B | 11.37B | 9.88B | 7.84B | 7.77B | 5.14B |
| Total Liabilities | 36.78B | 195.97B | 1.25T | 782.17B | 158.3B | 159.45B | 120.26B | 93.86B | 86.2B | 82.56B | 79.3B | 92.88B | 56.4B |
| Total Debt | 1.79B | 125.71B | 834.39B | 542.27B | 104.41B | 103.61B | 74.11B | 59.75B | 57.06B | 57.02B | 56.26B | 65.88B | 40.08B |
| Net Debt | -1.67B | 100.6B | 619.43B | 433.53B | 91.23B | 80.37B | 54.43B | 49.72B | 48.13B | 45.28B | 46.9B | 47.04B | 31.71B |
| Debt / Equity | 0.20x | 2.40x | 2.68x | 2.35x | 2.10x | 2.17x | 1.70x | 1.84x | 2.04x | 2.18x | 2.39x | 2.22x | 1.56x |
| Debt / EBITDA | 0.07x | 3.57x | 24.94x | 38.57x | 2.95x | 2.43x | 2.76x | 3.22x | 4.78x | 5.10x | 5.09x | 5.15x | 3.73x |
| Net Debt / EBITDA | -0.06x | 2.85x | 18.51x | 30.83x | 2.58x | 1.88x | 2.03x | 2.68x | 4.03x | 4.05x | 4.24x | 3.68x | 2.95x |
| Interest Coverage | 2.66x | 2.57x | 15.60x | 3.44x | 19.28x | 34.51x | 5.65x | 3.24x | 2.01x | 1.49x | 2.12x | 3.71x | 2.99x |
| Total Equity | 9.06B | 52.37B | 311.49B | 231B | 49.81B | 47.8B | 43.54B | 32.48B | 27.95B | 26.14B | 23.52B | 29.62B | 25.64B |
| Equity Growth % | -81.3% | -83.19% | 34.84% | 363.78% | 4.21% | 9.77% | 34.06% | 16.23% | 6.91% | 11.16% | -20.61% | 15.52% | - |
| Book Value per Share | 8.87 | 49.01 | 140.43 | 104.14 | 22.09 | 19.28 | 16.40 | 12.18 | 10.48 | 9.19 | 8.60 | 10.22 | 8.90 |
| Total Shareholders' Equity | 42.52B | 47.87B | 276.92B | 213.08B | 46.34B | 44.12B | 40.12B | 29.64B | 25.65B | 24.29B | 22.37B | 28.03B | 23.87B |
| Common Stock | 214.85M | 171.18M | 145.8B | 115.88B | 23.58B | 23.58B | 23.58B | 23.58B | 23.58B | 23.58B | 23.58B | 23.58B | 21.51B |
| Retained Earnings | 5.86B | 11.5B | 113.46B | 75.59B | 18.65B | 13.49B | 7.17B | 5.22B | 2.49B | 2.28B | 3.65B | 4.76B | 4.26B |
| Treasury Stock | -2.82B | -3.25B | 0 | 0 | 0 | -3.04B | -303.56M | -605.72M | -624.14M | 0 | -1.63B | -903.57M | -451.7M |
| Accumulated OCI | 1.5B | 39.44B | 16.36B | 20.56B | 3.9B | 9.88B | 9.47B | 1.23B | -10.39M | -1.78B | -3.44B | 387.79M | -1.66B |
| Minority Interest | 834.76M | 4.51B | 34.57B | 17.93B | 3.46B | 3.68B | 3.42B | 2.85B | 2.3B | 1.85B | 1.14B | 1.59B | 1.77B |
High leverage and margin compression
Total assets fell 6.2% from $248.3B in 2025Q4 to $232.9B in 2026Q1, while equity dropped 11.5% to $42.4B, as per reported figures, signaling a weakening balance sheet.
The sequential decline in total assets and equity suggests that the company is absorbing significant operational losses or impairments, consistent with the prior income statement showing a 54% drop in operating income. The reduction in retained earnings from $11.5B to $1.1B in one quarter indicates a substantial charge, possibly related to asset write-downs or dividend distributions, which warrants further investigation. This trajectory implies that the balance sheet is contracting, potentially limiting future financial flexibility.
Debt-to-equity rose to 2.55 in 2026Q1 from 2.40 in 2025Q4, with total debt at $119.3B, as per financial statements, indicating increased financial risk.
Despite a slight reduction in absolute debt from $125.7B to $119.3B, the equity base contracted faster, pushing leverage higher. The D/E ratio of 2.55 is significantly above peers like Tyson (0.48) and Hormel (0.36), suggesting that JBS is more vulnerable to interest rate fluctuations and refinancing risks. The high debt load may constrain capital allocation and increase interest expense, which could further pressure margins in a rising rate environment.
PP&E net of $60.3B and goodwill of $30.8B together represent 39% of total assets in 2026Q1, as reported in SEC filings, indicating a capital-intensive model with significant intangible risk.
The substantial investment in PP&E underscores the asset-heavy nature of meat processing, while goodwill of $30.8B (13% of assets) exposes the balance sheet to potential impairment if acquired businesses underperform. The decline in PP&E from $62.6B to $60.3B sequentially may reflect depreciation or asset sales, but the high fixed asset base suggests ongoing maintenance capex needs. Investors should monitor goodwill for impairment triggers, especially given the recent margin compression.
Retained earnings plummeted from $11.5B in 2025Q4 to $1.1B in 2026Q1, a 90% decline, as per financial data, signaling a major hit to equity quality.
The sharp reduction in retained earnings likely reflects a combination of net losses, dividend payouts, or accounting adjustments, which erodes the equity buffer. This decline, coupled with a 11.5% drop in total equity, suggests that the company is not retaining sufficient earnings to support its asset base. The equity quality appears strained, which may limit the company's ability to absorb future shocks without further leveraging.
Cash fell from $25.1B in 2025Q4 to $17.0B in 2026Q1, while the current ratio dipped to 1.50, as reported in financial statements, indicating a reduced cushion against short-term obligations.
The $8.1B drop in cash is concerning given the company's high debt load and the negative operating cash flow of -$4.1B in the same quarter. The current ratio of 1.50, though above 1, is below the 1.60 seen in the prior quarter and suggests tightening liquidity. This reduced buffer may increase reliance on external financing, especially if working capital needs persist, as indicated by the prior cash flow analysis.
Biological asset fair value changes and $30.8B goodwill may distort reported earnings, as per accounting disclosures, potentially masking underlying operational deterioration.
The balance sheet includes biological assets valued at fair value, which can introduce non-cash volatility into earnings, as noted in the company intelligence. Additionally, the large goodwill balance from past acquisitions may be at risk of impairment if the current margin compression persists, especially in the US beef segment. These factors could make the headline equity and asset figures misleading, and investors should adjust for these items when assessing the true financial health.
Quick answers to the most common questions about buying JBS stock.
As of 2025, Jbs N.V. (JBS) had total assets of $248.34B including $101.40B in current assets.
Jbs N.V. (JBS) carries total debt of $125.71B, offset by $25.98B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Jbs N.V. (JBS) has total shareholders' equity (book value) of $47.87B ($49.01 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Jbs N.V. (JBS) reported a current ratio of 1.60x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.